ArticleBMC endocrine disorders2025
Predictive effect of the triglyceride glucose index on abnormal blood glucose metabolism events in populations with sarcopenia: a cross-sectional study.
Article in BMC endocrine disorders, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundRecent studies reveal that obesity and reduced muscle mass are key factors implicated in insulin resistance (IR) and abnormal glycemic metabolism. Nonetheless, it remains ambiguous which demographic, particularly those with obesity or diminished muscle mass, exhibits a greater vulnerability to insulin resistance.
objectiveThe aim of this study is to investigate the relationship between insulin resistance assessed by the triglyceride and glucose index (TyG index) and abnormal blood glucose metabolism in individuals with both reduced muscle mass and obesity. Furthermore, we assess the efficacy of the TyG index in forecasting occurrences of atypical blood glucose metabolism within this particular demographic.
methodsThis cross-sectional study utilized data collected from adults who underwent a health assessment at our institution between December 2022 and September 2024. The evaluation of insulin sensitivity was conducted utilizing the TyG index, whereas muscle mass was quantified through bioelectrical impedance analysis (BIA). Logistic regression, Receiver Operating Characteristic (ROC) curve analysis, subgroup analysis, and interaction effect analysis were employed to evaluate the association between triglyceride-glucose index levels with subgroups based on different body masses.
resultsThis study comprised 1278 people with diminished muscle mass. We found a positive association between TyG index (OR = 7.73; 95% CI: 4.62-13.51; P < 0.001) and the risk of abnormal glucose metabolism among those who were overweight/obese. The analysis of the ROC curve revealed that the TyG index possesses a significant predictive capability for identifying abnormal glucose metabolism in individuals exhibiting diminished muscle mass (AUC = 0.906). This predictive value is particularly pronounced in those who do not present with overweight or obesity (AUC = 0.915), in contrast to its effectiveness in individuals who have both reduced muscle mass and overweight or obesity. Subgroup analyses confirmed the positive association of TyG index with abnormal blood glucose incidence.
conclusionThis study assessed the link between TyG and abnormal blood glucose metabolism events risk in people with sarcopenia and compared its predictive power for abnormal blood glucose metabolism events onset in those with low muscle mass but not overweight or obese. We recommend using the TyG index as the best predictive marker for assessing abnormal blood glucose metabolism events risk in individuals without concurrent overweight or obesity, regardless of their body mass index.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.